SKINDA

Stem Cell

HOME > Stem Cell

At SKINDA Clinic Ginza, we provide cultured stem cell therapy — previously difficult to offer in Korea —
with formal notification to Japan’s Ministry of Health, Labour and Welfare.

About Autologous Adipose-Derived Mesenchymal Stem Cell Therapy

SKINDA Clinic Ginza provides cultured autologous adipose-derived stem cell therapy, which is difficult to offer under Korea’s regulations, within the supervisory framework of Japan’s Ministry of Health, Labour and Welfare.
In accordance with Japan’s Act on the Safety of Regenerative Medicine, our clinic has submitted a Class II regenerative medicine provision plan to the Ministry of Health, Labour and Welfare and has been assigned plan numbers.

Plan: Treatment of chronic musculoskeletal pain by intravenous administration of autologous adipose-derived stem cells (ASC)
Plan number: PB3250282

Plan: Subcutaneous tissue regeneration by local administration of autologous adipose-derived stem cells (ASC)
Plan number: PB3260128

We strictly follow legal standards and safety management, and cells are cultured and processed at a CPC (Cell Processing Center) operating under Japanese government supervision.

What Are Mesenchymal Stem Cells (MSC)?

Our bodies contain cells that can multiply and differentiate on their own to replenish damaged tissue. These are called stem cells.
Among them, mesenchymal stem cells (MSC) are known to have

self-renewal capacity
the ability to differentiate into various cell types
immunomodulatory and anti-inflammatory effects

.
Sources of mesenchymal stem cells include

bone marrow
adipose (fat) tissue
umbilical cord

and others.
Of these, autologous adipose-derived mesenchymal stem cells (ASC) are relatively easy to harvest, highly safe and widely applicable in clinical practice, making them the most actively used cells in regenerative medicine today.

Differences from Stem Cell Therapy in Korea

Item	Advanced regenerative medicine institutions in Korea	SKINDA Clinic Ginza
Purpose	Limited to rare, intractable diseases (academic, non-commercial)	Legally permitted for treating general patients
Culturing	Culturing not legally permitted	CPC cell-processing company under Japanese government supervision
Cell count	As harvested (varies by institution)	Expanded to 200 million or more (official protocol)

Expected Effects (based on reports and research)

Autologous adipose-derived mesenchymal stem cells have been reported to have anti-inflammatory, immunomodulatory and tissue-regenerating effects, and the following changes may be expected.

Relief of chronic pain
Reduced systemic inflammation
Less fatigue and improved overall condition
Better tissue recovery
Potential improvement in age-related decline in function
Potential improvement in declining male/female function

* Results vary depending on the individual, and not all patients will experience the same results.
* This treatment is intended to treat disease and improve symptoms; it does not guarantee anti-aging or rejuvenation.

Who Can Receive This Treatment

Adults aged 20 or older
People with chronic pain
People with recurring inflammatory conditions
People experiencing a general decline in condition
People experiencing declining male/female function
People who did not respond sufficiently to previous treatments

Who Should Not Receive This Treatment

People currently being treated for a malignant tumor
Patients with active cancer
People with a serious infection
Patients with a serious immune disorder
People who are pregnant or breastfeeding
Anyone the attending physician judges unsuitable

Treatment Flow

■ First visit

At your first visit, we harvest in one session the fat to be used for the following six treatments.
Visit → Consultation → Fat harvesting

After harvesting, you book your preferred date for stem cell administration, 12 weeks or later.
The booked administration date can be changed up to 5 weeks in advance.
On the scheduled date, the cells are administered by IV drip over about 2 hours.

■ From the second treatment